Calibr, A Division Of Scripps Research
Clinical trials sponsored by Calibr, A Division Of Scripps Research, explained in plain language.
-
Scientists test 'Switchable' cell therapy to tame rogue immune systems
Disease control TerminatedThis early-stage study aimed to test the safety and effectiveness of a new two-part treatment for severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease. The treatment involved collecting a patient's own immune cells (T cells), engineering them to tar…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
15-Year watch begins for gene therapy patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study is monitoring people for 15 years after they received an experimental gene therapy called CLBR001. The goal is to check for any long-term side effects or safety issues that might appear long after the treatment. It is an observational study, meaning researchers are jus…
Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC